Needham initiated coverage on Generation Bio with a new price target
$GBIO
Biotechnology: Pharmaceutical Preparations
Health Care
Needham initiated coverage of Generation Bio with a rating of Buy and set a new price target of $50.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/19/2023 | Outperform → Market Perform | TD Cowen | |
| 11/8/2022 | $9.00 | Buy | Canaccord Genuity |
| 12/15/2021 | $40.00 → $10.00 | Market Outperform | JMP Securities |
| 12/15/2021 | $50.00 → $27.00 | Buy | Needham |
| 12/14/2021 | Outperform → Mkt Perform | William Blair |
Non-human primate data presented at ESGCT demonstrated selective in vivo delivery of mRNA with T cell-targeted lipid nanoparticle (ctLNP) Cash balance of $199.8 million expected to fund operations into 2H 2027 CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and third quarter 2024 financial results. "There is immense potential for a new class of redosable, selectively targeted in vivo genetic medicines to fulfill the needs of people living with diseases that remain unaddressed by existing treatment options," said Geoff
New non-human primate data show highly selective in vivo delivery of mRNA to T cells with a cell-targeted lipid nanoparticle (ctLNP) CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today presented data on its cell-targeted lipid nanoparticle (ctLNP) and immune-quiet DNA (iqDNA) platforms at the European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress. The company presented data showing that a single IV dose of its ctLNP delivered mRNA encoding a reporter protein to a majority of circulating T cells in non-human primates (NHPs). In the
CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024 at 10:20 a.m. ET in New York. A live webcast of the presentation will be available on the investor section of the company's website at investors.generationbio.com. A replay will be available there for 30 days following the event. About Generation Bio Generation Bio is innovating non-viral genetic medicines
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
Company entered into strategic collaboration with Moderna to use Generation Bio's proprietary non-viral genetic medicine delivery system for two liver disease programs and to co-develop novel targeting for immune cells Factor VIII expression data in non-human primates for wholly-owned hemophilia A program expected in 2023 First quarter 2023 cash balance of $288.6 million expected to fund operations into 2025; additional $47.5 million from Moderna collaboration received in second quarter 2023 CAMBRIDGE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent disea
CAMBRIDGE, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Yalonda Howze, J.D. has been appointed chief legal officer and secretary. "We are delighted to welcome Yalonda to the Generation Bio leadership team and look forward to drawing on her extensive legal expertise as we continue to execute on our vision of reaching the full potential of genetic medicine," said Geoff McDonough, M.D., president and chief executive officer of Generation Bio. "Generation Bio is pursuing an ambitious goal to develop lifelong, titratable gain of function DNA th
CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and second quarter 2022 financial results. "We are advancing our leading non-viral genetic medicine platform to unlock the potential of durable, redosable non-viral DNA therapeutics, and we have made significant progress in establishing the proprietary technologies necessary to realize our vision," said Geoff McDonough, M.D., president and chief executive officer of Generation Bio. "This quarter, process development and scaling of rapid enzymatic synthesis (RES) for prod
10-Q - Generation Bio Co. (0001733294) (Filer)
8-K - Generation Bio Co. (0001733294) (Filer)
EFFECT - Generation Bio Co. (0001733294) (Filer)
SC 13G/A - Generation Bio Co. (0001733294) (Subject)
SC 13G/A - Generation Bio Co. (0001733294) (Subject)
SC 13G/A - Generation Bio Co. (0001733294) (Subject)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
4 - Generation Bio Co. (0001733294) (Issuer)
TD Cowen downgraded Generation Bio from Outperform to Market Perform
Canaccord Genuity initiated coverage of Generation Bio with a rating of Buy and set a new price target of $9.00
JMP Securities reiterated coverage of Generation Bio with a rating of Market Outperform and set a new price target of $10.00 from $40.00 previously